Wafik S. El-Deiry: Manuscript by Tajiknia et al on Synergistic anti-tumor activity

Wafik S. El-Deiry shared a post on X:

“Manuscript from eldeiry lab, Legorreta Cancer Center by Vida Tajiknia, Am J Cancer Res, 2024 In PubMed.

Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation.”

Title: Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation

Authors: Vida Tajiknia, Maximilian Pinho-Schwermann, Praveen R Srinivasan, Liz Hernandez Borrero, Leiqing Zhang, Kelsey E Huntington and Wafik S El-Deiry 

Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center   Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.